ANPI Angiotech Pharmaceuticals - Common Shares (MM)

Introducing SharpGuard(TM) Microsurgical Guarded Knives For Use In Ophthalmic Surgery VANCOUVER, Nov. 8 /PRNewswire-FirstCall/ -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), a global specialty pharmaceutical and medical device company, today announced that it plans to exhibit its SharpGuard(TM) product line as well as all of its Sharpoint(TM) brand ophthalmic disposable surgical instruments at the upcoming American Academy of Ophthalmology (AAO) annual meeting. About the SharpGuard(TM) Guarded Knives Product Line The SharpGuard(TM) product line is comprised of microsurgical guarded knives for use in ophthalmic surgery. Key features of the SharpGuard(TM) product line include: - Guarded sheath designed to eliminate or minimize sharps injuries - Sharpoint(TM) premium quality microsurgical blades manufactured by proprietary Infinite Edge(TM) technology process - Ergonomic grip designed for precise control and comfort - Designed to comply with OSHA bloodborne pathogens regulations Angiotech will host Booth # 2411 at the AAO annual meeting in New Orleans, LA, taking place from November 10-13, 2007. About Angiotech Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at http://www.angiotech.com/. SHARPGUARD(TM), SHARPOINT(TM) and INFINITE EDGE(TM) are trademarks of Surgical Specialties Corporation, a wholly-owned subsidiary of Angiotech Pharmaceuticals, Inc. (C)2007 Angiotech Pharmaceuticals, Inc. (C)2007 Surgical Specialties Corporation. All Rights Reserved. CONTACT: Jodi Regts, Senior Manager, Investor Relations and Corporate Communications, Angiotech Pharmaceuticals, Inc., (604) 221-7930, DATASOURCE: Angiotech Pharmaceuticals, Inc. CONTACT: Jodi Regts, Senior Manager, Investor Relations and Corporate Communications, Angiotech Pharmaceuticals, Inc., (604) 221-7930,

Copyright